Cf

Translate Bio Announces Second Quarter 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, August 5, 2021
Company, Cf, Infection, Clinical trial, Data, American Thoracic Society, U.S. Securities and Exchange Commission, Investment, Vaccine, Collaboration, Patent, Ministry of Education (Malaysia), PCD, Private Securities Litigation Reform Act, Technology, Risk, DNAI1, Earnout, Sanofi Pasteur, IND, Partnership, Time, Pulmonology, Translation, Therapy, Animal, Patient, COVID-19, Twitter, MRT, Food and Drug Administration, Sanofi, Cystic fibrosis transmembrane conductance regulator, ATS, RNA, Sanofi–Translate Bio COVID-19 vaccine, Research, RNA transfection, Cystic fibrosis, Liver, Safety, Conference, Acquisition, Security (finance), GLOBE, Pharmaceutical industry

LEXINGTON, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat or prevent debilitating or life-threatening diseases, today announced financial results for the second quarter ended June 30, 2021 and reviewed recent corporate updates.

Key Points: 
  • This transaction is a validation of our mRNA platform and a testament to the talented Translate Bio team.
  • Translate Bio ended the second quarter of 2021 with $667.2 million in cash, cash equivalents and investments and 75,343,712 shares of common stock outstanding.
  • General and administrative expenses of $11.9 million during the second quarter of 2021, compared to $8.6 million for the same period in 2020.
  • Translate Bio is also pursuing the development of mRNA vaccines for infectious diseases under a collaboration with Sanofi Pasteur.

Vertex Appoints Stuart A. Arbuckle as Chief Operating Officer

Retrieved on: 
Wednesday, August 4, 2021
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, Articles, Business, VRTX, Economy, Vertex Pharmaceuticals, Chief operating officer

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Stuart A. Arbuckle has been appointed as the companys Executive Vice President, Chief Operating Officer (COO), effective immediately.

Key Points: 
  • Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Stuart A. Arbuckle has been appointed as the companys Executive Vice President, Chief Operating Officer (COO), effective immediately.
  • Mr. Arbuckle has served as Vertexs Executive Vice President and Chief Commercial Officer since 2012 and expanded his role to include oversight of operations earlier this year.
  • He also has played a key role evolving our operating model to ready us for continued expansion into new diseases and geographic areas.
  • In his new role, Stuart will ensure that we are best positioned to maximize the potential of our innovative therapies, secure access for patients and drive continued growth for Vertex.

Vertex CEO Reshma Kewalramani, MD to join Ginkgo Bioworks Board of Directors

Retrieved on: 
Tuesday, August 3, 2021
Plants, Reshma Kewalramani, Taxa, Ginkgo Bioworks, FASN, Ginkgo

BOSTON, Aug. 3, 2021 /PRNewswire/ -- Ginkgo Bioworks , Inc. ("Ginkgo") today announced that Reshma Kewalramani, M.D., FASN, Chief Executive Officer and President at Vertex, will join its board of directors.

Key Points: 
  • BOSTON, Aug. 3, 2021 /PRNewswire/ -- Ginkgo Bioworks , Inc. ("Ginkgo") today announced that Reshma Kewalramani, M.D., FASN, Chief Executive Officer and President at Vertex, will join its board of directors.
  • "We are honored to have Dr. Kewalramani join our board of directors.
  • "I am excited to join Ginkgo's board of directors at such a pivotal time for the company," said Reshma Kewalramani, M.D., FASN, Chief Executive Officer and President at Vertex.
  • Dr. Kewalramani plans to join as the eighth board member for Ginkgo Bioworks.

Cadillac Fairview Commits to 'Transforming Communities for a Vibrant Tomorrow'

Retrieved on: 
Thursday, June 17, 2021
Cadillac Fairview, Cf, Real estate

TORONTO, June 17, 2021 /CNW/ - Cadillac Fairview (CF) is formally unveiling its company purpose, "Transforming Communities for a Vibrant Tomorrow," coinciding with the release of its annual Corporate Responsibility Report, published today.

Key Points: 
  • TORONTO, June 17, 2021 /CNW/ - Cadillac Fairview (CF) is formally unveiling its company purpose, "Transforming Communities for a Vibrant Tomorrow," coinciding with the release of its annual Corporate Responsibility Report, published today.
  • Since then, the entire company has leaned into its important role as a city builder, unlocking opportunities that transform communities.
  • "In a year unlike any other, CF has relied heavily on its purpose to navigate the global pandemic," explained John Sullivan, President and CEO, Cadillac Fairview.
  • Continually striving to make a positive impact in communities where it operates by promoting social connection, growth, and a sustainable future, CF's Purpose is Transforming Communities For A Vibrant Tomorrow.

CF Foundation Launches New Collaboration With Deep Science Ventures to Overcome Challenges to Developing Genetic Therapies for CF

Retrieved on: 
Tuesday, June 15, 2021
Other Health, Research, General Health, Pharmaceutical, Philanthropy, Genetics, Foundation, Science, Biotechnology, Other Philanthropy, Other Science, Health, Medical specialties, Channelopathies, Cystic fibrosis, Cf, Clinical medicine, Vertex Pharmaceuticals, the Path to a Cure, the Cystic Fibrosis Foundation, THE PATH TO A CURE, THE CYSTIC FIBROSIS FOUNDATION

Today, the CF Foundation announced a new collaboration with venture creator Deep Science Ventures, focused on uncovering and designing new technologies with the potential to overcome challenges to developing genetic therapies for cystic fibrosis.

Key Points: 
  • Today, the CF Foundation announced a new collaboration with venture creator Deep Science Ventures, focused on uncovering and designing new technologies with the potential to overcome challenges to developing genetic therapies for cystic fibrosis.
  • The collaboration will leverage Deep Science Ventures ideation-based innovation and venture creation to identify promising early technologies.
  • Deep Science Ventures and the CF Foundation will work together to assess pressing barriers to genetic therapies in CF, explore the feasibility of potential solutions, and design proof-of-concept studies.
  • We are excited to apply our expertise together with the CF Foundation to significantly accelerate progress towards future therapies for cystic fibrosis, said Kerstin Papenfuss, PhD, associate director of pharmaceuticals at Deep Science Ventures.

CF Foundation Invests Up to $8.4M in SpliSense for the Development of Potential Rare Mutation Therapy

Retrieved on: 
Thursday, May 13, 2021
Philanthropy, Health, Other Science, Foundation, General Health, Research, Science, Cystic fibrosis, Medical specialties, Branches of biology, Channelopathies, Organ systems, Cf, Ivacaftor, Cystic Fibrosis Canada

The objective is to generate a proof-of-concept for the ASO technology in cystic fibrosis.

Key Points: 
  • The objective is to generate a proof-of-concept for the ASO technology in cystic fibrosis.
  • As a result, splicing mutations block the synthesis of normal CFTR proteins.
  • The Foundation funds more CF research than any other organization, and nearly every CF drug available today was made possible because of Foundation support.
  • The CF Foundation is a donor-supported nonprofit organization.

Cadillac Fairview Announces New Head of Europe in Support of Global Growth

Retrieved on: 
Wednesday, March 17, 2021
Cadillac Fairview, Ontario Teachers' Pension Plan, Finance, Fairview, Cadillac, Cf, Economy, Companies

TORONTO and LONDON, March 17, 2021 /PRNewswire/ -- Cadillac Fairview (CF) is pleased to announce the appointment of Jenny Hammarlund as Managing Director, Head of Europe.

Key Points: 
  • TORONTO and LONDON, March 17, 2021 /PRNewswire/ -- Cadillac Fairview (CF) is pleased to announce the appointment of Jenny Hammarlund as Managing Director, Head of Europe.
  • "As the global real estate arm of the Ontario Teachers' Pension Plan, which has over $200 billion of assets, CF is focused on growth and international diversification," said Mr. Osborne.
  • The purchase represents a critical foothold in Europe, and an important contribution to the global growth and strategy of Ontario Teachers'.
  • Media Contact: Meg Sharpley, North Strategic on behalf of Cadillac Fairview, 905-517-9390, [email protected]

View, Inc. and CF Acquisition Corp. II Announce Closing of Business Combination

Retrieved on: 
Monday, March 8, 2021
Finance, Geography of California, Cantor Fitzgerald, Money, Howard Lutnick, Special-purpose acquisition company, Cf, Silicon Valley

MILPITAS, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- View, Inc. (View), a Silicon Valley-based smart window company, announced today that it has completed its business combination with CF Finance Acquisition Corp. II (Nasdaq: CFII) (CF II), a special purpose acquisition company sponsored by Cantor Fitzgerald, L.P. (Cantor Fitzgerald).

Key Points: 
  • MILPITAS, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- View, Inc. (View), a Silicon Valley-based smart window company, announced today that it has completed its business combination with CF Finance Acquisition Corp. II (Nasdaq: CFII) (CF II), a special purpose acquisition company sponsored by Cantor Fitzgerald, L.P. (Cantor Fitzgerald).
  • The Business Combination was approved by CF II stockholders in a special meeting held on March 5, 2021.
  • CF Finance Acquisition Corp. II was led by Chairman and Chief Executive Officer Howard W. Lutnick.
  • Neither View nor CF II gives any assurance that either View or CF II will achieve its expectations.

Claire's Place Foundation Expands COVID-19 Programs to Support People with Cystic Fibrosis

Retrieved on: 
Thursday, December 17, 2020
Fictional characters, Medical specialties, Fiction, Channelopathies, Claire Bennet, Cf, Claire's, Claire Littleton, Cystic fibrosis, Cystic Fibrosis Trust

"My daughter Claire certainly has been our angel as we endured this difficult year," said Claire's Place Foundation Executive Director Melissa Yeager.

Key Points: 
  • "My daughter Claire certainly has been our angel as we endured this difficult year," said Claire's Place Foundation Executive Director Melissa Yeager.
  • In 2020, the Claire's Place Foundation Work Proudly Program helped 15 people with CF and caregivers learn a trade that can be done from anywhere.
  • is a 501(c)(3) non-profit organization providing support to children and families affected by cystic fibrosis (CF).
  • Recipient of Los Angeles Business Journal's "Small Nonprofit of the Year," the foundation provides grants to families affected by CF, offering both emotional and financial support.

Royalty Pharma Acquires Additional Royalty Interest From the Cystic Fibrosis Foundation

Retrieved on: 
Monday, November 2, 2020
Life sciences, Royalty Pharma, Medical specialties, Biotechnology, Vertex Pharmaceuticals, Cystic Fibrosis Foundation, Cystic fibrosis, Cf

NEW YORK, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement to acquire the residual royalty interest in Vertex Pharmaceuticals, Inc.s cystic fibrosis (CF) treatments owned by the Cystic Fibrosis Foundation.

Key Points: 
  • NEW YORK, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement to acquire the residual royalty interest in Vertex Pharmaceuticals, Inc.s cystic fibrosis (CF) treatments owned by the Cystic Fibrosis Foundation.
  • Pablo Legorreta, Royalty Pharmas Founder and Chief Executive Officer, stated, We are excited to build on our long-standing relationship with the CF Foundation.
  • As part of previous agreements with the CF Foundation, Royalty Pharma purchased all of the CF Foundations royalty interests on Vertexs CF franchise.
  • MTS Health Partners and Mintz Levin acted as advisors to the Cystic Fibrosis Foundation on the transaction and Goodwin Procter, Dechert and Maiwald acted as legal advisors to Royalty Pharma.